Curis Provides Updated Trial Data Of Blood Cancer Treatment

Curis Inc. (CRIS), a biotechnology company focused on cancer treatment, Wednesday announced updated data from its ongoing phase 1/2 study of CA-4948 in patients with acute myeloid leukemia or high-risk myelodysplastic syndromes.

According to data from a cutoff date of February 8 in 15 patients, 8 MDS and 7 AML patients, bone marrow blast reductions were observed at all tested doses in 8 of 9 evaluable patients. Four objective responses were recorded with signs of hematologic recovery.

The company said two abstracts for CA-4948 have been accepted for oral and poster presentation at the European Hematology Association 2021 Virtual Congress (EHA), which will be held virtually from June 9-17, 2021.

"We are very pleased to report this clinical update on our first-in-class IRAK4 kinase inhibitor, CA-4948, as an anticancer agent for patients with acute myeloid leukemia and myelodysplastic syndromes for whom multiple prior lines of therapy have been unsuccessful," said James Dentzer, President and Chief Executive Officer of Curis.

"The clinical data published in the abstract this morning are consistent with our preliminary findings reported late last year showing that CA-4948 has, in addition to encouraging safety characteristics, clear potential to reduce leukemic blasts in late-line patients, along with early signs of hematologic recovery. We look forward to providing updated safety, pharmacodynamic, and efficacy data, as well as data from additional patients and nonclinical combination synergy data at EHA next month."

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Shares of HSBC Holdings Plc were gaining in London and Hong Kong trading after the Asia-focused lender reported Monday that its first-half profit more than doubled, despite weak revenues. Looking ahead, the company said while uncertainties remain, the outlook is more positive with evidence of growth in strategic areas. After Disney World, retail giant Walmart Inc. (WMT) makes it mandatory for all its employees to wear mask on their facilities in the "high-risk" states where the Delta variant of Coronavirus has become menacing. The orders will be in effect immediately. The Center for Disease Control and Prevention... Generac Power Systems is recalling 325,735 units of Generac and DR 6500 Watt and 8000 Watt portable generators for potential risk of finger amputation and crushing hazards, a statement by the U.S. Consumer Product Safety Commission (CPSC) showed. These include 4,575 units sold in Canada.
Follow RTT